



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Kim Clark  
✉ kim.clark@kedrion.com

RECEIVED 09 May 2024  
ACCEPTED 15 May 2024  
PUBLISHED 29 May 2024

CITATION  
Geng B, Clark K, Evangelista M and Wolford E  
(2024) Corrigendum: Low rates of headache  
and migraine associated with intravenous  
immunoglobulin infusion using a 15-minute  
rate escalation protocol in 123 patients with  
primary immunodeficiency.  
*Front. Immunol.* 15:1430313.  
doi: 10.3389/fimmu.2024.1430313

COPYRIGHT  
© 2024 Geng, Clark, Evangelista and Wolford.  
This is an open-access article distributed under  
the terms of the [Creative Commons Attribution  
License \(CC BY\)](#). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or reproduction  
is permitted which does not comply with  
these terms.

# Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency

Bob Geng<sup>1</sup>, Kim Clark<sup>2\*</sup>, Mark Evangelista<sup>3</sup> and Eric Wolford<sup>2</sup>

<sup>1</sup>Division of Allergy & Immunology, University of California, San Diego, CA, United States, <sup>2</sup>Global Medical Department, Bio Products Laboratory, Ltd., Elstree, United Kingdom, <sup>3</sup>Biostatistics Department, Atlantic Research Group, Charlottesville, VA, United States

## KEYWORDS

IVIg, headache, migraine, primary immunodeficiencies, rate escalation, pooled

## A corrigendum on

**Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency**

by Geng B, Clark K, Evangelista M and Wolford E (2023). *Front. Immunol.* 13:1075527.  
doi: 10.3389/fimmu.2022.1075527

## Error in figure/table caption

In the published article, there was an error in the caption for **Figure 4** as published. The current caption to **Figure 4** mistakenly describes the figure as depicting weeks on the x-axis when it is actually reporting number of infusions. The figure caption was displayed as “Incidence of product-related headache and migraine by infusion number, number of events (A) 5% IVIG formulation (108 patients for weeks 1–5, then 75 patients for weeks 6–18) (B) 10% IVIG formulation (48 patients)”. The corrected caption appears below.


Incidence of product-related headache and migraine by infusion number, number of events (A) 5% IVIG formulation (108 patients for infusions 1–5, then 75 patients for infusions 6–18) (B) 10% IVIG formulation (48 patients).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 4** Incidence of product-related headache and migraine by infusion number, number of events (A) 5% IVIG formulation (108 patients for infusions 1–5, then 75 patients for infusions 6–18) (B) 10% IVIG formulation (48 patients).